OCCAM Immune, a Mount Sinai research organization, will sequence and map cells from samples collected in CRI's immunotherapy trials.

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

NEW YORK – Abbisko Therapeutics on Monday said it dosed the first patient with FGF19-overexpressing liver cancer in a registrational study to establish the safety and efficacy of its FGFR4 inhibitor ...

NEW YORK – Myrio, an Australian T-cell therapy developer, will soon begin testing its PHOX2B PC-CAR T-cell therapy in neuroblastoma patients in a Phase I clinical trial, the company announced Monday.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.